SCHEMBL360994

SCHEMBL360994

COC(=O)c1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 20/20 1.00
AKT2 P31751 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361419 0.92 AKT1 (1.00) AKT1AKT2
SCHEMBL361131 0.89 AKT1 (1.00) AKT1AKT2
SCHEMBL17004148 0.86 AKT1 (0.80) AKT1AKT2
SCHEMBL361230 0.85 AKT1 (1.00) AKT1AKT2
SCHEMBL17004162 0.85 AKT1 (0.81) AKT1AKT2
SCHEMBL360604 0.84 AKT1 (1.00) AKT1AKT2
SCHEMBL361783 0.84 AKT1 (1.00) AKT1AKT2
SCHEMBL360121 0.84 AKT2 (1.00) AKT1AKT2
SCHEMBL17011609 0.84 AKT1 (0.72) AKT1AKT2
SCHEMBL12986011 0.84 AKT1 (1.00) AKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593451-B1 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER IP GMBH (DE) 2015-08-19 EP claimed
US-8975265-B2 Substituted imidazo[1,2-a]pyrimidines and —pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-10 US claimed
US-20130190332-A1 Substituted Imidazo[1,2-a]pyrimidines and -pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-25 US claimed
EP-2593451-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES Bayer Intellectual Property GmbH (DE) 2013-05-22 EP claimed
WO-2012007345-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-19 WO claimed
EP-2593451-B1 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER IP GMBH (DE) 2015-08-19 EP disclosed
EP-2593451-B1 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER IP GMBH (DE) 2015-08-19 EP disclosed
US-8975265-B2 Substituted imidazo[1,2-a]pyrimidines and —pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-10 US disclosed
US-8975265-B2 Substituted imidazo[1,2-a]pyrimidines and —pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-10 US disclosed
US-20130190332-A1 Substituted Imidazo[1,2-a]pyrimidines and -pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-25 US disclosed
US-20130190332-A1 Substituted Imidazo[1,2-a]pyrimidines and -pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-25 US disclosed
WO-2012007345-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190332-A1 Substituted Imidazo[1,2-a]pyrimidines and -pyridines PIK3CA, PIK3CD, PIK3CB AKT1 26/4885AKT2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.